Brokers Issue Forecasts for Shattuck Labs FY2024 Earnings

Shattuck Labs, Inc. (NASDAQ:STTK) – Equities researchers at Leerink Partnrs issued their FY2024 earnings per share (EPS) estimates for Shattuck Labs in a research note issued to investors on Monday, March 17th. Leerink Partnrs analyst F. Khurshid forecasts that the company will earn ($1.42) per share for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Shattuck Labs’ Q4 2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.93) EPS and FY2026 earnings at ($0.93) EPS.

Separately, Leerink Partners began coverage on Shattuck Labs in a research note on Monday. They issued an “outperform” rating and a $4.00 price objective for the company. Four research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.50.

Shattuck Labs Price Performance

Shares of NASDAQ STTK opened at $1.19 on Thursday. The stock has a market capitalization of $56.81 million, a P/E ratio of -0.78 and a beta of 1.66. Shattuck Labs has a 1 year low of $0.94 and a 1 year high of $11.76. The company has a 50-day moving average price of $1.24 and a 200-day moving average price of $1.59.

Institutional Trading of Shattuck Labs

Several institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its stake in Shattuck Labs by 63.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company’s stock worth $96,000 after buying an additional 10,667 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Shattuck Labs by 0.9% during the third quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock worth $3,184,000 after buying an additional 8,133 shares in the last quarter. MetLife Investment Management LLC raised its position in shares of Shattuck Labs by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after purchasing an additional 13,859 shares during the last quarter. State Street Corp lifted its stake in shares of Shattuck Labs by 7.8% in the third quarter. State Street Corp now owns 766,410 shares of the company’s stock worth $2,675,000 after buying an additional 55,579 shares in the last quarter. Finally, Barclays PLC raised its holdings in Shattuck Labs by 299.5% in the 3rd quarter. Barclays PLC now owns 54,311 shares of the company’s stock valued at $189,000 after buying an additional 40,717 shares during the period. 58.74% of the stock is currently owned by institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.